标题：孟鲁司特钠联合雾化吸入布地奈德对RSV毛细支气管炎的疗效及血清炎症因子的影响

      作者：陈瑜 1，肖劲花 1，黄冬蕾 1，金慧敏 1，柳希 2    (暨南大学附属深圳市宝安区妇幼保健院药剂科 1、儿科 2，广东 深圳 518101)

      卷次： 2018年29卷9期

      【摘要】 目的 观察孟鲁司特钠联合雾化吸入布地奈德治疗呼吸道合胞病毒(RSV)毛细支气管炎的疗效，并探讨其对患儿血清炎症因子的影响。方法 选取2016年2月至2017年5月期间深圳市宝安区妇幼保健院儿科收治的RSV毛细支气管炎患儿202例为研究对象，根据随机数表法分为观察组与对照组，每组101例，对照组予雾化吸入布地奈德治疗，观察组联合应用孟鲁司特钠口服，疗程 7 d；比较两组患儿的临床指标及血清免疫球蛋白E(IgE)、白细胞介素-8 (IL-8)及肿瘤坏死因子-α (TNF-α)水平的变化。结果 观察组患儿的喘息缓解、哮鸣音消失、咳嗽消失及住院时间分别为(3.44±1.42) d、(5.62±1.75) d、(6.56±2.01) d、(6.78±2.19) d，明显少于对照组的(4.58±1.57) d、(6.59±2.62) d、(7.43±2.62) d、(7.91±2.94) d，差异均有统计学意义(P<0.05)；治疗后，观察组患儿的血清TNF-α、IL-8及 IgE水平分别为(59.45±21.53) pg/mL、(17.68±6.18) pg/mL、(167.24±69.75) IU/mL，明显低于对照组的(81.48±31.25) pg/mL、(25.82±8.35) pg/mL、(190.36±54.18) IU/mL，差异均有统计学意义(P<0.05)。结论 孟鲁司特钠联合雾化吸入布地奈德治疗RSV毛细支气管炎可有效降低患儿血清炎症因子水平，促进临床症状的缓解。
      【关键词】 呼吸道合胞病毒；毛细支气管炎；孟鲁司特钠；布地奈德；炎症因子
      【中图分类号】 R562.2+1 【文献标识码】 A 【文章编号】 1003—6350（2018）09—1212—03

Effect of montelukast sodium combined with aerosol inhalation of budesonide in the treatment of respiratorysyncytial virus induced capillary bronchitis and its influence on serum inflammatory factors.
CHEN Yu 1, XIAOJin-hua 1, HUANG Dong-lei 1, JIN Hui-min 1, LIU Xi 2. Department of Pharmacy 1, Department of Pediatrics 2, Shenzhen BaoanDistrict Maternal and Child Health Care Hospital Affiliated to Jinan University, Shenzhen 518101, Guangdong, CHINA
【Abstract】 Objective To observe the effect of montelukast sodium combined with aerosol inhalation ofbudesonide in the treatment of respiratory syncytial virus (RSV) induced capillary bronchitis, and to investigate its effecton serum inflammatory factors. Methods A total of 202 children with RSV induced capillary bronchitis in Departmentof Pediatrics in Baoan District Maternal and Child Health Care Hospital Affiliated to Jinan University from February2016 to May 2017 were selected as the research objects and divided into observation group and control group accordingto the random number table method, with 101 cases in each group. The control group received budesonide inhalationtherapy, and the observation group received montelukast sodium combined with aerosol inhalation of budesonide, with 7days as a treatment course. The clinical indexes, serum immunoglobulin E (IgE), interleukin-8 (IL-8), and tumor necro-sis factor-α (TNF-α) were compared between the two groups. Results The asthma remission, wheeze disappearance,cough disappearance, and hospitalization time in observation group were (3.44±1.42) d, (5.62±1.75) d, (6.56±2.01) d, (6.78±2.19) d, respectively, which were significantly less than (4.58±1.57) d, (6.59±2.62) d, (7.43±2.62) d, (7.91±2.94) d in controlgroup. After treatment, the TNF-α, IL-8, and IgE in observation group was (59.45±21.53) pg/mL, (17.68±6.18) pg/mL,(167.24±69.75) IU/mL, respectively, which were significantly lower than (81.48±31.25) pg/mL, (25.82±8.35) pg/mL,(190.36 ± 54.18) IU/mL in control group. Conclusion Montelukast sodium combined with aerosol inhalation ofbudesonide can effectively reduce the level of serum inflammatory factors and promote the remission of symptoms inchildren with RSV induced capillary bronchitis.
      【Key words】 Respiratory syncytial virus; Capillary bronchitis; Montelukast sodium; Budesonide; Inflammatory factors·论 著·doi:10.3969/j.issn.1003-6350.2018.09.009